JPWO2021080983A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021080983A5 JPWO2021080983A5 JP2022523453A JP2022523453A JPWO2021080983A5 JP WO2021080983 A5 JPWO2021080983 A5 JP WO2021080983A5 JP 2022523453 A JP2022523453 A JP 2022523453A JP 2022523453 A JP2022523453 A JP 2022523453A JP WO2021080983 A5 JPWO2021080983 A5 JP WO2021080983A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- months
- combination
- composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000575 trastuzumab Drugs 0.000 claims description 56
- 238000002648 combination therapy Methods 0.000 claims description 53
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 41
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 41
- 229960004117 capecitabine Drugs 0.000 claims description 41
- 230000004083 survival effect Effects 0.000 claims description 39
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 claims description 38
- 229950003463 tucatinib Drugs 0.000 claims description 38
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 24
- 229940125714 antidiarrheal agent Drugs 0.000 claims description 14
- 239000003793 antidiarrheal agent Substances 0.000 claims description 14
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 4
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 27
- 238000000034 method Methods 0.000 description 110
- 208000003174 Brain Neoplasms Diseases 0.000 description 12
- 206010059282 Metastases to central nervous system Diseases 0.000 description 12
- 206010012735 Diarrhoea Diseases 0.000 description 9
- 238000011319 anticancer therapy Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 4
- 206010061818 Disease progression Diseases 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 239000000611 antibody drug conjugate Substances 0.000 description 1
- 229940049595 antibody-drug conjugate Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229950008835 neratinib Drugs 0.000 description 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962923659P | 2019-10-21 | 2019-10-21 | |
| US62/923,659 | 2019-10-21 | ||
| PCT/US2020/056489 WO2021080983A1 (en) | 2019-10-21 | 2020-10-20 | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553041A JP2022553041A (ja) | 2022-12-21 |
| JPWO2021080983A5 true JPWO2021080983A5 (https=) | 2023-10-13 |
| JP2022553041A5 JP2022553041A5 (https=) | 2023-10-13 |
Family
ID=73598175
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022523453A Pending JP2022553041A (ja) | 2019-10-21 | 2020-10-20 | Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240092936A1 (https=) |
| EP (1) | EP4048275A1 (https=) |
| JP (1) | JP2022553041A (https=) |
| KR (1) | KR20220086627A (https=) |
| CN (1) | CN114746094A (https=) |
| AU (1) | AU2020370058A1 (https=) |
| CA (1) | CA3156820A1 (https=) |
| IL (1) | IL292332A (https=) |
| MX (1) | MX2022004699A (https=) |
| WO (1) | WO2021080983A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3060407A1 (en) | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| CN115252793A (zh) * | 2022-08-15 | 2022-11-01 | 新疆医科大学第三附属医院 | 一种乳腺癌靶向抑制因子及其在乳腺癌治疗中的用途 |
| CN116473923B (zh) * | 2023-05-29 | 2024-05-14 | 杭州剂泰医药科技有限责任公司 | 一种奈拉替尼固体分散体组合物及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| AU668384B2 (en) | 1992-03-12 | 1996-05-02 | Alkermes Controlled Therapeutics, Inc. | Controlled release ACTH containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| RU2629116C2 (ru) | 2011-10-14 | 2017-08-24 | Эррэй Биофарма Инк. | Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их |
| BR122020010643B1 (pt) | 2011-10-14 | 2022-05-17 | Array Biopharma Inc | Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida |
| CA3060407A1 (en) * | 2017-04-28 | 2018-11-01 | Seattle Genetics, Inc. | Treatment of her2 positive cancers |
| AU2020381495A1 (en) * | 2019-11-15 | 2022-05-19 | Seagen Inc. | Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate |
| JP2023517078A (ja) * | 2020-03-11 | 2023-04-21 | シージェン インコーポレイテッド | ツカチニブを用いてｈｅｒ２突然変異を有するがんを処置する方法 |
-
2020
- 2020-10-20 MX MX2022004699A patent/MX2022004699A/es unknown
- 2020-10-20 IL IL292332A patent/IL292332A/en unknown
- 2020-10-20 US US17/768,290 patent/US20240092936A1/en not_active Abandoned
- 2020-10-20 KR KR1020227016776A patent/KR20220086627A/ko not_active Ceased
- 2020-10-20 AU AU2020370058A patent/AU2020370058A1/en active Pending
- 2020-10-20 CN CN202080077966.9A patent/CN114746094A/zh active Pending
- 2020-10-20 JP JP2022523453A patent/JP2022553041A/ja active Pending
- 2020-10-20 CA CA3156820A patent/CA3156820A1/en active Pending
- 2020-10-20 EP EP20812457.8A patent/EP4048275A1/en not_active Withdrawn
- 2020-10-20 WO PCT/US2020/056489 patent/WO2021080983A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021155426A5 (https=) | ||
| JP2020517696A5 (https=) | ||
| JP2017031160A5 (https=) | ||
| RU2011125518A (ru) | Антиангиогенная терапия, применяемая для лечения рака молочной железы | |
| JP2012509889A5 (https=) | ||
| WO2022026767A1 (en) | Treatment of migraine | |
| JP2018514510A5 (https=) | ||
| JP2020535149A5 (https=) | ||
| JP2024038034A5 (https=) | ||
| JP2021518394A5 (https=) | ||
| Sorensen | The role of intravenous immunoglobulin in the treatment of multiple sclerosis | |
| JP2021523233A5 (https=) | ||
| KR20240032789A (ko) | 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물 | |
| US6274566B1 (en) | Methods for treating mammals with modified alginates and pectins | |
| JPWO2021097220A5 (https=) | ||
| IL292332A (en) | Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab | |
| JPWO2021080983A5 (https=) | ||
| JPWO2020118252A5 (https=) | ||
| JP2007517885A5 (https=) | ||
| US3681497A (en) | Therapeutic methods of employing hydrogen maleate salt of n-(d-6-methyl-8-isoergolenyl)-n{40 ,n{40 -diethyl-carbamide | |
| IL317954A (en) | Treatment of hematological malignancies with galectin-9 inhibitory antibodies | |
| JPWO2022026767A5 (https=) | ||
| JPWO2021138264A5 (https=) | ||
| JPWO2022117799A5 (https=) | ||
| Car et al. | A double-blind multicentre comparison of diclofenac sodium and naproxen in osteoarthrosis of the hip |